Examination of correcting K2 deficiency impact on children’s bone health published
in prestigious international journal

 

OSLO, NORWAY AND EDISON, NJ (12 JUNE 2018) — A new pilot study1 evaluating vitamin D and K
status in children with and without low-energy fractures has published in Nutrients, an international, peerreviewed
journal for studies related to Human Nutrition.

The publication of this study, “Decreased Levels of Circulating Carboxylated Osteocalcin in Children with
Low Energy Fractures: A Pilot Study,” is significant because it adds to the growing body of evidence that
Vitamin K2 is a beneficial nutrient for both children and adults, according to NattoPharma Chief Medical
Officer Dr. Hogne Vik.

“This trial reaffirms the real health benefits improving K2 status delivers,” says Vik. “More importantly, it
shines a light on the true impact improving K2 status has on children, our most precious resource.”

According to Dr. Vladimir Badmaev, author of the paper and principal and founder of American Medical
Holdings, Inc., “The epidemiological evidence indicates a disturbing growth in the number of cases of lowenergy
fractures in healthy children and adolescents. There are multiple risk factors that may contribute to
this growing health concern, and among the leading consideration are deficient or insufficient nutrition
and nutrients, including calcium, vitamin D and vitamin K.”

Dr. Badmaev explains that the particular role of vitamin K2, especially menaquinone-7 (MK-7), has been
highlighted in the literature and distinguished from vitamin K1 in maintaining calcium homeostasis and
healthy skeletal system. “The epidemiological and clinical research provides a new nutritional paradigm for
efficient, safe delivery of calcium that requires co-supplementation with both vitamins D and K.”

The gravitas for this study, which was recently presented at The World Congress on Osteoprosis,
Osteoarthritis, and Musculoskeletal Diseases, the world’s leading clinical conference on bone, joint, and
muscle health, is increased by Nutrients, a leading European journal with a high impact factor (a measure
of how often it is cited by other researchers), selecting it for publication.

“It cannot be overstated the importance of every possible opportunity to advance industry and academic
understanding of this essential nutrient,” Vik concludes. “The findings are so very significant, as they
provide supporting evidence to the clinical research NattoPharma has already spearheaded. Not only has
our research identified children as a group most deficient in Vitamin K2, but that just 45mcg of K2 (as
NattoPharma’s MenaQ7®) daily improves K status and increases the activation of osteocalcin, the Kdependent
protein responsible for binding calcium to the bone mineral matrix, therefore improving bone
health.”

Reference:
Popko J, Karpinski M, Chojnowska S, Maresz K, Milewski R, Badmaev V, Schurgers L. Decreased Levels of Circulating
Carboxylated Osteocalcin in Children with Low Energy Fractures: A Pilot Study. Nutrients 2018, 10(6), 734.
https://doi.org/10.3390/nu10060734

XXX

About NattoPharma and MenaQ7®
NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development.
NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best
documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical
substantiation, and international patents granted and pending; and now the new MenaQ7® Full Spectrum,
which delivers menaquinones 6, 7, 8, and 9. The company has a multi-year research and development
program to substantiate and discover the health benefits of Vitamin K2 for applications in the marketplace
for functional food and dietary supplements. With a global presence, the company established its North
American subsidiary, NattoPharma USA, Inc., in Edison, NJ, and NattoPharma R&D Ltd. in Cyprus. For more
information, visit www.nattopharma.com or www.menaq7.com.

For more information, please contact:
Kate Quackenbush, NattoPharma Director of Communications
Phone: 609-643-0749 x 220
E-mail: kate.quackenbush@nattopharma.com